[LHN]

Longevity glossary and profiles

Plain-English background on compounds, tests, mechanisms, regulators and interventions mentioned in claim checks.

20 entities

Peptide

BPC-157

Risk:High risk

A peptide discussed online for tissue repair and injury recovery claims.

Status:Not approved

Checked Jun 27, 2026

Peptide

TB-500

Risk:High risk

A peptide name commonly used in injury-recovery and performance-recovery claims.

Status:Not approved

Checked Jun 27, 2026

Peptide

Semax

Risk:High risk

A peptide discussed for neurological and nootropic claims.

Status:Non-US or unclear status

Checked Jun 27, 2026

Peptide

Epitalon

Risk:Experimental

A peptide discussed in anti-aging and sleep-related claims.

Status:Not approved

Checked Jun 27, 2026

Peptide

GHK-Cu

Risk:High risk

A copper peptide used in cosmetic and peptide-marketing claims.

Status:Status unclear

Checked Jun 27, 2026

Peptide

MOTS-c

Risk:Experimental

A mitochondrial-derived peptide discussed for metabolism and longevity.

Status:Not approved

Checked Jun 27, 2026

Risk:High risk

An mTOR-inhibiting drug discussed as a geroscience candidate.

Status:Off-label

Checked Jun 27, 2026

Risk:Moderate risk

A diabetes drug studied and debated as a longevity candidate.

Status:Off-label

Checked Jun 27, 2026

Risk:Moderate risk

A glucose-modulating drug discussed because of animal longevity findings.

Status:Off-label

Checked Jun 27, 2026

Mechanism

NAD+

Risk:Moderate risk

A molecule involved in cellular energy and repair pathways.

Status:Status unclear

Checked Jun 27, 2026

Supplement

NMN

Risk:Moderate risk

A NAD precursor supplement discussed for energy, metabolism and aging.

Status:Supplement status

Checked Jun 27, 2026

Supplement

NR

Risk:Moderate risk

A NAD precursor supplement commonly compared with NMN.

Status:Supplement status

Checked Jun 27, 2026

Risk:Lower risk

Models that estimate biological age or risk from DNA methylation patterns.

Status:Status unclear

Checked Jun 27, 2026

Risk:Lower risk

A broad concept for estimating aging-related state from biomarkers or models.

Status:Status unclear

Checked Jun 27, 2026

Risk:Moderate risk

Cells that have stopped dividing and can influence inflammation, repair and disease risk.

Status:Status unclear

Checked Jun 27, 2026

Supplement

Fisetin

Risk:Moderate risk

A flavonoid supplement discussed as a possible senolytic.

Status:Supplement status

Checked Jun 27, 2026

Risk:Experimental

An experimental approach that aims to shift cellular state without fully erasing identity.

Status:Experimental

Checked Jun 27, 2026

Mechanism

OSK factors

Risk:High risk

A subset of reprogramming factors discussed in cellular rejuvenation research.

Status:Experimental

Checked Jun 27, 2026

Regulator

FDA

Risk:Lower risk

The US regulator for drugs, biologics, devices, foods and many health claims.

Status:Approved for this use

Checked Jun 27, 2026

Risk:Lower risk

A US-run registry and results database for clinical studies.

Status:Status unclear

Checked Jun 27, 2026